C. Luna (Buenos Aires, Argentina), A. Liapikou (Athens, Greece)
Prognostic factors for mortality in adults with pneumonia due to influenza A (H1N1)
O. Pérez-Bautista, A. Ramírez-Venegas, C. García-Sancho, R. Hérnandez-Zenteno, R. Sansores, R. Pérez-Padilla (Mexico City, Mexico)
|   |
Predictive value of plasma D-dimer in patients with community-acquired pneumonia (CAP)
O. Omelianenko, A. Makarevich, E. Amelchenko, T. Rybina (Minsk, Belarus)
| |
Criteria for predicting the course and outcome of pneumonia
A. Gorelov, I. Umarova, S. Rudakova (Saint-Petersburg, Russian Federation)
| |
Biomarkers for the prognostic assessment and disease severity evaluation in community-acquired pneumonia (CAP)
O. Omelianenko, A. Makarevich, E. Anmelchenko, T. Rybina (Minsk, Belarus)
| |
Admission CRP and D-dimer levels can identify high-risk patients with community-acquired pneumonia
D. Agapakis, D. Tsantilas, P. Psarris, E. Massa, P. Kotsaftis, K. Tziomalos, A. Hatzitolios (Thessaloniki, Greece)
| |
Safety and efficacy of CURB65 guided antibiotic therapy in community-acquired pneumonia
J. D. Chalmers, A. Singanayagam, A. R. Akram, V. Wood, G. Choudhury, P. Mandal, A. T. Hill (Edinburgh, United Kingdom)
| |
Biomarkers and community acquired pneumonia (CAP) severity
E. Mincholé, S. Fandos, A. B. Lasierra, E. Vera, E. Forcen, V. Moya, A. García de Jalón, S. Bello (Zaragoza, Spain)
| |
Thyroid function in community-acquired pneumonia (CAP) patients: Pattern, relationship with severity and outcomes, need for invasive mechanical ventilation and vasopressor support
O. Omelianenko, A. Makarevich, E. Amelchenko, T. Rybina (Minsk, Belarus)
| |
C Reactive Protein (CRP), procalcitonin (PCT) and proadrenomedullin (Pro-ADM), as markers to discriminate bacterial, viral and mixed community acquired pneumonia (CAP)
A. B. Lasierra, S. Fandos, E. Mincholé, E. Vera, M. A. Ruiz, M. J. Revillo, A. García de Jalón, S. Bello (Zaragoza, Spain)
| |
C-reactive protein (CRP) in the prognosis of complications of parapneumonic effusions (PPE)
T. Pejcic, I. Stankovic, I. Djorjdevic, T. Radjenovic, D. Nastasijevic, Z. Ciric (Nis, Republic Of Serbia)
| |
Community acquired pneumonia (CAP) 30 days mortality and biomarkers
A. B. Lasierra, S. Fandos, E. Mincholé, D. Nieto, L. Martinez, A. Boldova, A. García de Jalón, S. Bello (Zaragoza, Spain)
| |
Increased Indoleamine 2,3-dioxygenase (IDO) activity as predictors of severity and outcome in patients with pneumonia
Y. Suzuki, T. Suda, K. Yokomura, Y. Nakano, K. Chida (Hamamatsu, Japan)
| |
Contribution of AT-III and protein-C to the assessment of severity of community-acquired pneumonia
D. Agapakis, D. Tsantilas, P. Psarris, E. Massa, P. Kotsaftis, K. Tziomalos, A. Hatzitolios (Thessaloniki, Greece)
| |
Assessment of prognostic scores for 30-day mortality prediction in hospitalised patients with health care associated pneumonia (HCAP)
M. Carrabba, M. Zarantonello, P. Bonara, C. Hu, G. Fabio (Italy)
| |
Impact of high body mass index in mortality in hospitalized patients with CAP: Results from the CAPO international cohort study
P. Peyrani, T. Wiemken, S. Aliberti, R. Cosentini, F. Blasi, R. Riquelme, J. Rello, A. Torres, J. Ramirez, CAPO Investigators (Louisville, United States Of America; Milan, Italy; , Chile; Tarragon, Barcelona, Spain)
| |
Performance of CURB-65 and eCURB severity assessment for health care associated pneumonia in an emergency department
N. Dean, J. Jones, B. Jones, S. Brown, T. Allen, D. Valenti, A. Jephson (Salt Lake City, United States Of America)
| |
Comparison of the predictive rules PSI and CRB-65 for assessing severity of community-acquired pneumonia among patients over 65 years
O. Ochoa-Gondar, E. Salsench-Serrano, A. Vila-Corcoles, C. de Diego-Cabanes, F. Ramos-Perez, EPIVAC Study Group (Tarragona, Spain)
| |
CURB-65 pneumonia severity assessment adapted for electronic decision support
N. Dean, J. Jones, B. Jones, S. Brown, T. Allen, D. Valenti, A. Jephson (Salt Lake City, United States Of America)
| |